Eli Lilly’s retatrutide reduces obstructive sleep apnea symptoms in trials

Trials demonstrate retatrutide’s impact on sleep apnea

Eli Lilly’s experimental drug retatrutide, designed to treat obesity, has shown potential in reducing symptoms of obstructive sleep apnea (OSA) in recent clinical trials. According to findings reported by Gizmodo, the drug mimics GLP-1, GIP, and the hormone glucagon, positioning it as part of the next generation of medications for obesity and metabolic disorders.

Two trials involving approximately 700 participants demonstrated that retatrutide significantly reduced episodes of apnea and hypopneas compared to a placebo. In one trial, over half of the participants using retatrutide experienced remission of their OSA or saw their condition downgraded to mild, reducing the need for positive airway pressure machines. These results were published in the New England Journal of Medicine.

Regulatory outlook and limitations

The FDA is expected to approve retatrutide for obesity treatment next year, with potential for additional approval to treat OSA. Eli Lilly’s tirzepatide, a similar drug, received FDA approval for OSA in late 2024, signaling regulatory openness to treating sleep disorders with metabolic drugs.

However, retatrutide’s benefits appear limited to individuals with obesity or overweight conditions. The drug may not significantly impact OSA patients who do not fall into these categories, as excess body weight is not the sole risk factor for the disorder.

Broader context for obesity and metabolic drugs

This development follows earlier reports suggesting that GLP-1 drugs, like those developed by Eli Lilly and Novo Nordisk, may slow biological aging by reducing molecular markers associated with age. Those findings, presented at the Aging Research & Drug Discovery conference, remain unverified but highlight the broader potential of metabolic drugs beyond weight loss.

Separately, a European study funded by Pierre Fabre linked GLP-1 medications such as semaglutide and tirzepatide to dermatological side effects, including hair loss and nail issues. This underscores the need for founders and operators in the pharmaceutical space to weigh both the therapeutic benefits and risks of these drugs as they advance through clinical trials.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Retatrutide’s potential to address OSA alongside obesity could expand the market for metabolic drugs beyond traditional weight-loss indications. For founders and operators in the pharmaceutical and biotech sectors, this signals an opportunity to explore multi-indication drugs that target interconnected conditions like obesity, diabetes, and sleep disorders. The FDA’s recent approval of tirzepatide for OSA suggests a growing regulatory appetite for such therapies, which may accelerate development timelines for similar drugs. However, the limitations of retatrutide—its lack of efficacy for non-obese OSA patients—highlight the importance of precise patient segmentation in drug development and marketing strategies.

Related on Lazyfounder

• Eli Lilly
• Food and Drug Administration
• More health news
• Eli Lilly and Novo Nordisk report GLP-1 drugs may slow biological aging
• GLP-1 drugs linked to hair loss and nail issues in European study